Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.
Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.
Fresenius will be included in the Dow Jones Sustainability Index Europe (DJSI Europe) for the first time as from 23 September 2019. The selected companies must demonstrate continuous improvement with regard to sustainability and are assessed by analysts from asset manager RobecoSAM.
Fresenius will be included in the Dow Jones Sustainability Index Europe (DJSI Europe) for the first time as from 23 September 2019. The selected companies must demonstrate continuous improvement with regard to sustainability and are assessed by analysts from asset manager RobecoSAM.
The price increase for hospital services in Germany has been set at 3.66% for 2020. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.
The price increase for hospital services in Germany has been set at 3.66% for 2020. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.
Fresenius Helios patients in Germany can soon start accessing letters from their doctors, test results and other medical documents over an online platform – the Helios Patients Portal. This new portal can also be used to make appointments. The confidentiality of patient data is assured through the use of two-factor authentification. All 86 of the company’s hospitals, 126 medical care centers and eight prevention centers throughout Germany are being gradually linked to the Helios Patients Portal. The company is also developing a portal for doctors.
Fresenius Helios patients in Germany can soon start accessing letters from their doctors, test results and other medical documents over an online platform – the Helios Patients Portal. This new portal can also be used to make appointments. The confidentiality of patient data is assured through the use of two-factor authentification. All 86 of the company’s hospitals, 126 medical care centers and eight prevention centers throughout Germany are being gradually linked to the Helios Patients Portal. The company is also developing a portal for doctors.
Fresenius Medical Care, the world’s leading provider of dialysis products and services, today announced the publication of its 2019 global annual medical report. Titled “Global Insights, Local Promise: Transforming Healthcare Through Interconnected Intelligence,” it outlines how the company is harnessing the power of an increasingly interconnected world to pioneer solutions that can have a large-scale impact on patient care.
The report also explores ways to apply insights gained in different markets on a global level, and how best practices can be adapted to specific market needs.
In addition to articulating experiences in dialysis care across diverse regions, the report delves deeper into several focus areas relevant to the healthcare industry and the evolution of kidney care:
- Expanding home therapies to give dialysis patients more control of their lives and improve treatment outcomes.
- Improving transplant access through open communication and collaboration among multiple stakeholders.
- Embracing diversity and an interdisciplinary approach to improve value-based care in kidney disease.
- Developing predictive models to identify dialysis clinics that are encountering problems or in need of additional support, and,
- Clarifying and explaining the role of nutrition in the prevention and treatment of chronic kidney disease.
Dr. Frank Maddux, Global Chief Medical Officer of Fresenius Medical Care, said: “Interconnected thinking is central to our way of working at Fresenius Medical Care and it demonstrates our commitment to making a difference in the lives of patients. The people of Fresenius Medical Care, all around the world, have always been our greatest asset. Harnessing the full potential of their interconnected intelligence can boost innovation, advance medical progress, develop better therapies, and help drive the transformation of healthcare systems worldwide.”
Spectra Laboratories, a wholly-owned subsidiary of Fresenius Medical Care North America, broke ground on a 200,000-square-foot (approx. 18,500 square meters) laboratory in Southaven, Mississippi yesterday. The project is expected to create more than 300 jobs over the next three years. Spectra Laboratories offers renal-specific laboratory services, using state-of-the-art equipment, automated specimen processing, and reporting applications. At Spectra’s new build-to-suit facility, employees will conduct comprehensive testing, analysis, and reporting to ensure the best possible outcomes for patients.